Abstract
Background Various levels of lockdown implemented to contain the rapid spread of COVID-19 are not long-term solutions due to socioeconomic implications.
Methods To inform safe reopening, we used an augmented SEIR model to project the impact of 1) interventions and potential new epidemic trajectories arising from super spreader (SS) events and/or international travel and 2) re-introducing strong behavioural interventions on resurgence trajectories.
Results Our model suggests that 50% behaviour intervention effectiveness (BIE) (from enforced social distancing during lockdown, early in the epidemic), along with 50% isolation intervention effectiveness (IIE) (from increased testing and isolating infected individuals) was achieved during lockdown, which curbed COVID-19 transmission in Malaysia. Post-lockdown, BIE plays a minimal role if IIE reaches or exceeds 46.9% when other variables are held constant. At IIE of 30% and BIE of 21.3%, SS events of 5,000 active cases risks COVID-19 resurgence, with 4-year projected 12.9mn cumulative cases and 1.1mn deaths. Earlier action to increase BIE to 50% on day 98 compared to day 111, prevented an additional 21,401 recovered cases and 257 deaths.
Conclusion Until a safe and effective vaccine is widely available, the risk of COVID-19 resurgence from large SS events warrants caution in decisions to allow for mass gatherings and regular international travel.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors did not receive specific funding for this work. The authors would like to thank Khazanah Research Institute for allowing the authors to apportion time for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study does not involve direct human subjects and relies on secondary publicly available data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email: jan.ayub{at}krinstitute.org, gregory.ho{at}krinstitute.org
Data Availability
Data is available upon request.
